Document is current
Any future updates will be listed below
-
Authors
Haj-Yehia, Elias
Michel, Lars
Mincu, Raluca I.
Rassaf, Tienush
Totzeck, Matthias
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FU356/12-2)
Deutsche Forschungsgemeinschaft,Germany (RA969/12-1)
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Accepted: 10 February 2025
First Online: 19 February 2025
Declarations
:
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: E.H.-Y. reports personal fees and others from AstraZeneca, which are outside the submitted work. L.M. reports personal fees from Bayer, Alnylam, AstraZeneca, IFFM e. V. and from Bund der Niedergelassenen Kardiologen (BNK), which are outside the submitted work. M.T. and T.R. report personal fees and others from Edwards and Novartis, Bristol Myers Squibb, Bayer, Daiichi Sankyo and Astra Zeneca, which are outside the submitted work. T.R. cofounded Bimyo, a company focusing on the development of cardioprotective peptides. All other authors declare no conflict of interest.
